Sign in
CompletedPhase 4

Ferric Carboxymaltose Versus Iron Sucrose for Treating Anemia in Pregnant Women

Key facts

Who runs it
CMH Multan Institute of Medical Sciences
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
60 people enrolled
Started
1 Feb 2024
Ended
30 Sept 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Iron Carboxymaltose
  • Iron Sucrose Injection
Record updated
6 April 2025

Who can take part

Age
20 years to 45 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • 28-34 weeks of gestation
  • Iron deficiency anemia (IDA): IDA will be labelled if Hemoglobin is <10 gm% and serum Ferritin < 30 ng/ml

Who cannot take part

  • history of allergic reaction to intravenous iron infusion
  • Hepatitis (serum transaminases more than 1.5 times the upper limit of normal) and HIV infection
  • serum creatinine level of more than 2.0 mg/dL

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial aimed to determine whether intravenous ferric carboxymaltose is more useful than iron sucrose for treating anemia in pregnant women.

Read full original descriptionShow less

The main question it aimed to answer was:

Is intravenous ferric carboxymaltose is more useful than iron sucrose for treating iron deficiency anemia in pregnant women.

Sixty pregnant women with iron deficiency anemia were enrolled to one of two intravenous treatments.

* Participants in ferrous carboxymaltose group received a maximum dose of 1000 mg per sitting diluted in 200 ml 0.9% normal saline and administered as an IV infusion over 30 min. * Participants in iron sucrose group were administered an infusion of 300 mg in 200 ml NS over 15-20 min twice weekly till dosage was completed, not exceeding 600 mg per week.

The 2 groups in the trial

  • CarboxymaltoseTreatment being tested

    Intravenous infusion

    Treatment: Iron Carboxymaltose

  • SucroseExisting treatment, for comparison

    Intravenous infusion

    Treatment: Iron Sucrose Injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anemia in Pregnant Women
Record updated
6 April 2025